(MENAFN- GetNews)


"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Insight, 2025"Growing Market Opportunity Drives Investment in Chronic Inflammatory Demyelinating Polyneuropathy Treatments as Novel C1s Inhibitors and FcRn Antagonists Show Clinical Promise.

DelveInsight's comprehensive "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Insight, 2025 " report reveals a dynamic therapeutic landscape with key companies developing several pipeline drugs to address this rare autoimmune disorder affecting peripheral nerves.

CIDP represents a significant unmet medical need. The autoimmune-mediated inflammatory disease causes progressive motor and sensory deficits, manifesting as proximal and distal muscle weakness, numbness, paraesthesia, and sensory ataxia, often leading to severe disability due to demyelination and secondary axonal loss of peripheral nerves.

Clinical Pipeline Shows Promise in 2025

The CIDP therapeutic pipeline has witnessed remarkable advancement in 2025, with Sanofi's riliprubart leading the charge as a potential first-in-class treatment. This IgG4 humanized monoclonal antibody selectively inhibits activated C1s in the classical complement pathway, demonstrating significant clinical benefits in Phase II trials. In March 2025, riliprubart showed substantial plasma neurofilament light (NfL) level reductions, with greater reductions correlating with stronger functional improvements measured by Inflammatory Neuropathy Cause and Treatment (INCAT) Disability scores.

The compound achieved remarkable efficacy across patient populations. 87% of standard-of-care-treated participants showed improved or sustained disease activity at 24 weeks, while 92% of treatment-naïve patients demonstrated improvement or stability. Riliprubart has received FDA Orphan Drug Designation and is currently advancing through two pivotal Phase III trials, MOBILIZE and VITALIZE, enrolling up to 300 participants across 28 countries.

Immunovant's batoclimab represents another breakthrough in the pipeline, targeting the Neonatal Crystallizable Fragment Receptor (FcRn) with potential immunomodulating activity. Phase 2b results announced in March 2025 demonstrated a 1.8-point improvement in adjusted INCAT disability scores and an impressive 84% responder rate in patients achieving IgG reduction greater than 70%.

CIDP Companies Transform Treatment Paradigm

A new entrant, Dianthus Therapeutics, has initiated the CAPTIVATE Phase III trial for DNTH103 (claseprubart), another C1s inhibitor demonstrating the industry's focus on complement pathway modulation. The global, multicenter study aims to enroll approximately 480 participants with a unique patient-friendly design where everyone starts with active medication rather than placebo, reflecting growing confidence in this therapeutic approach.

To access detailed CIDP therapeutic assessments, clinical trial analyses, and competitive intelligence, download DelveInsight's CIDP Pipeline report .

CIDP Competitive Landscape and Strategic Implications

DelveInsight's comprehensive analysis reveals a highly concentrated pipeline with significant opportunities for strategic positioning. The focus on complement pathway inhibition and FcRn antagonism represents a paradigm shift from traditional immunosuppressive approaches toward targeted, mechanism-based therapies. These novel approaches offer potential advantages including convenient subcutaneous administration, reduced infection risks, and improved safety profiles compared to broad immunosuppression.​

The orphan drug designation pathway provides attractive incentives for pharmaceutical companies, including seven years of market exclusivity, tax credits for clinical testing, and FDA fee waivers. With current CIDP treatments facing patent expirations and generic competition, innovative companies have unprecedented opportunities to capture market share.

For more information about the CIDP competitive landscape, download DelveInsight's CIDP Pipeline Insight report .

About DelveInsight's CIDP Pipeline Report

DelveInsight's report provides a comprehensive analysis of the evolving therapeutic landscape, featuring detailed drug profiles, clinical trial assessments, mechanism of action analysis, and commercial evaluations. The report covers pipeline products across all development stages, from discovery through Phase III, offering pharmaceutical executives critical intelligence for strategic decision-making.

The report includes in-depth coverage of therapeutic assessments by product type, stage, route of administration, and molecule type, highlighting inactive pipeline products and identifying collaboration opportunities. Key questions addressed in the report include current treatment scenarios, emerging therapies, clinical study statuses, and regulatory designations that define competitive positioning.

Table of Contents

1. Introduction

2. Executive Summary

3. CIDP: Overview

4. Introduction

5. CIDP Pipeline Therapeutics

6. CIDP Therapeutic Assessment

7. CIDP – DelveInsight's Analytical Perspective

8. CIDP Late Stage Products (Phase III)

9. CIDP Mid-Stage Products (Phase II)

10. CIDP Early Stage Products (Phase I)

11. CIDP Preclinical and Discovery Stage Products

12. CIDP Inactive Products

13. CIDP Key Companies

14. CIDP Key Products

15. CIDP- Unmet Needs

16. CIDP Market Drivers and Barriers

17. CIDP Future Perspectives and Conclusion

18. CIDP Analyst Views

19. CIDP Key Companies

20. Appendix

About DelveInsight

DelveInsight is a leading business consulting and market research firm focused on pharma and healthcare. The company provides comprehensive market intelligence, competitive analysis, and strategic consulting services to pharmaceutical, biotechnology, and medical device companies worldwide.

MENAFN15102025003238003268ID1110203249